PTC Therapeutics reports positive interim Phase 2 data for PTC518 in Huntington's disease

PTC THERAPEUTICS, INC.

Interim data from PIVOT-HD Phase 2 study shows dose-dependent lowering of HTT protein in blood, with mean 30% reduction at 10mg dose.
PTC518 treatment well tolerated; no treatment-related serious adverse events or dose-limiting toxicities reported.
No CSF NfL treatment-related spikes; trend towards lowering of CSF NfL levels after 12 weeks.
Conference call held June 21, 2023 at 8:00 AM EDT to discuss data; slides furnished as Exhibit 99.2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.